Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy
ConclusionsMortality remains significantly high in patients with acromegaly, irrespectively of disease status, as long as the follow-up is sufficiently long with a low rate of patients lost to follow-up. Therapy strategy including radiotherapy does not have an impact on mortality. Oncological causes of death currently outweigh the cardiovascular causes. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - January 12, 2024 Category: Endocrinology Source Type: research
Oculo-facio-cardio-dental (OFCD) syndrome: a case report
ConclusionOculo-facio-cardio-dental syndrome (OFCD) is an extremely rare condition characterized by abnormalities in the eyes, face, heart, and teeth, often caused by variants in the BCOR gene. Radiculomegaly, or enlarged dental roots, is a key diagnostic feature of OFCD, and early detection is crucial for preventing future dental complications. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - January 4, 2024 Category: General Medicine Source Type: research
Paradoxical GH increase after oral glucose load in subjects with and without acromegaly
ConclusionsGH-Par response may be defined as a 20% increase in the first 90 min after glucose challenge. GH-Par, common in acromegaly and associated with an increased prevalence of glucose metabolism abnormalities, is found also in a subset of non-acromegalic subjects with high IGF-1 levels, suggesting its possible involvement in the early phase of the disease. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - January 1, 2024 Category: Endocrinology Source Type: research
Erectile function and androgen and estrogen beta receptor gene polymorphisms in acromegalic men
ConclusionsMen with acromegaly have a high prevalence of erectile dysfunction, but it does not appear to be correlated with treatments, testosterone levels and AR/ER-beta signaling. Nonetheless, a shorter CA polymorphic trait (ERbeta) is associated with the presence of cardiomyopathy. If confirmed, these data may suggest an association between an incorrect hormonal balance and increased cardiovascular risk in acromegaly subjects. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - January 1, 2024 Category: Endocrinology Source Type: research
Acromegaly increases depressive symptoms and reduces quality of life of cohabitants
ConclusionThe chronic process of acromegaly and the external appearance of patients with this disease can negatively affect both the patients and the people living with them. Physicians being aware of this effect and taking counteractive measures may contribute positively to the course of acromegaly. (Source: Pituitary)
Source: Pituitary - December 30, 2023 Category: Endocrinology Source Type: research
The direct impact of pegvisomant on osteoblast functions and bone development
ConclusionThis study provides a first evidence of the impact of PEG on osteoblast functions both in vitro and in vivo. These findings may have clinically relevant implications for the management of skeletal health in subjects with acromegaly. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - December 30, 2023 Category: Endocrinology Source Type: research
Acromegaly increases depressive symptoms and reduces quality of life of cohabitants
ConclusionThe chronic process of acromegaly and the external appearance of patients with this disease can negatively affect both the patients and the people living with them. Physicians being aware of this effect and taking counteractive measures may contribute positively to the course of acromegaly. (Source: Pituitary)
Source: Pituitary - December 30, 2023 Category: Endocrinology Source Type: research
The direct impact of pegvisomant on osteoblast functions and bone development
ConclusionThis study provides a first evidence of the impact of PEG on osteoblast functions both in vitro and in vivo. These findings may have clinically relevant implications for the management of skeletal health in subjects with acromegaly. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - December 30, 2023 Category: Endocrinology Source Type: research
Pasireotide - potential treatment option for McCune Albright-associated acromegaly
Eur J Endocrinol. 2023 Dec 21:lvad173. doi: 10.1093/ejendo/lvad173. Online ahead of print.ABSTRACTOnly 30% of patients with McCune Albright syndrome (MAS)-associated acromegaly achieve biochemical control under first-generation somatostatin receptor ligands (fg-SRLs), while pegvisomant fails to normalize IGF-I in >20% of cases. Here, we report all the patients with MAS-associated acromegaly treated with pasireotide long-acting release (LAR) in our center. Pasireotide LAR 20 mg/month resulted in rapid and long-term insulin-like growth factor 1 (IGF-I) normalization in patient #1 and #3. Patient #3 was resistant to fg-SRL...
Source: Cancer Control - December 21, 2023 Category: Cancer & Oncology Authors: Mirela-Diana Ilie G érald Raverot Aude Brac de la Perri ère Source Type: research
Pasireotide - potential treatment option for McCune Albright-associated acromegaly
Eur J Endocrinol. 2023 Dec 21:lvad173. doi: 10.1093/ejendo/lvad173. Online ahead of print.ABSTRACTOnly 30% of patients with McCune Albright syndrome (MAS)-associated acromegaly achieve biochemical control under first-generation somatostatin receptor ligands (fg-SRLs), while pegvisomant fails to normalize IGF-I in >20% of cases. Here, we report all the patients with MAS-associated acromegaly treated with pasireotide long-acting release (LAR) in our center. Pasireotide LAR 20 mg/month resulted in rapid and long-term insulin-like growth factor 1 (IGF-I) normalization in patient #1 and #3. Patient #3 was resistant to fg-SRL...
Source: European Journal of Endocrinology - December 21, 2023 Category: Endocrinology Authors: Mirela-Diana Ilie G érald Raverot Aude Brac de la Perri ère Source Type: research
Pasireotide - potential treatment option for McCune Albright-associated acromegaly
Eur J Endocrinol. 2023 Dec 21:lvad173. doi: 10.1093/ejendo/lvad173. Online ahead of print.ABSTRACTOnly 30% of patients with McCune Albright syndrome (MAS)-associated acromegaly achieve biochemical control under first-generation somatostatin receptor ligands (fg-SRLs), while pegvisomant fails to normalize IGF-I in >20% of cases. Here, we report all the patients with MAS-associated acromegaly treated with pasireotide long-acting release (LAR) in our center. Pasireotide LAR 20 mg/month resulted in rapid and long-term insulin-like growth factor 1 (IGF-I) normalization in patient #1 and #3. Patient #3 was resistant to fg-SRL...
Source: European Journal of Endocrinology - December 21, 2023 Category: Endocrinology Authors: Mirela-Diana Ilie G érald Raverot Aude Brac de la Perri ère Source Type: research
A Novel Somatostatin Receptor Ligand for Human ACTH- and GH-secreting Pituitary Adenomas
Eur J Endocrinol. 2023 Dec 20:lvad171. doi: 10.1093/ejendo/lvad171. Online ahead of print.ABSTRACTSomatostatin receptor ligands have come to play a pivotal role in the treatment of both ACTH- and GH-secreting pituitary adenomas. Clinical efficacy averages 30-50%, thus a considerable number of patients with Cushing's disease or acromegaly remain unresponsive to this therapeutic approach. HTL0030310 is a new somatostatin receptor ligand selective for subtype 5 over subtype 2, thus with a different receptor profile compared to clinical somatostatin receptor ligands. The aim of the present study was to evaluate the effect of H...
Source: European Journal of Endocrinology - December 20, 2023 Category: Endocrinology Authors: Daniela Regazzo Serena Avallone Cliona P MacSweeney Eugenia Sergeev David Howe Alex Godwood Kirstie A Bennett Alastair J H Brown Matt Barnes Gianluca Occhi Mattia Barbot Diego Faggian Maria Pia Tropeano Marco Losa Giovanni Lasio Carla Scaroni Francesca Pe Source Type: research
Acromegaly presented with acne vulgaris: a retrospective study with 123 cases
ConclusionsOur findings provide preliminary evidence of the high prevalence of adult acne in acromegaly patients, and a high rate of late-onset acne as well. Traditional anti-acne treatments are less effective. Acne could be considerably relieved by treating acromegaly. Acne remission positively correlated with IGF-1 decline as well, which revealed the correlation between acne and IGF-1. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - December 19, 2023 Category: Endocrinology Source Type: research
